ACA
GSK icon

Aptus Capital Advisors’s GSK GSK Stock Holding History

Aptus Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-57,600
Closed -$3.38M – 450
2019
Q4 		$3.38M Buy
57,600
+10,400
+22% +$578K 0.24% 73
2019
Q3 		$2.52M Buy
+47,200
New +$2.43M 0.14% 93

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Aptus Capital Advisors's GSK Position: Q2 2026 in Review

Aptus Capital Advisors increased its GSK (GSK) stake by 70% in Q2 2026, buying an estimated $268K and bringing the position to 12,300 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #721.

Aptus Capital Advisors first reported a position in GSK in Q3 2019 and has held it in 12 quarters since. The position peaked at $3.39M in Q4 2019. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Aptus Capital Advisors held 12,300 shares of GSK worth $645K as of Q2 2026.
  • Aptus Capital Advisors bought 5,059 GSK shares in Q2 2026, an estimated $268K.
  • GSK made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #721 holding.
  • Aptus Capital Advisors first reported a position in GSK in Q3 2019 and has held it in 12 quarters since.
  • Aptus Capital Advisors's GSK position peaked at $3.39M in Q4 2019.
  • 1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.